FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature


1Department of Fundamental Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Epalinges, Switzerland. 2Hamamatsu University School of Medicine, Hamamatsu, Japan. 3SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. 4University of Missouri, Columbia, Missouri, USA. 5Institute of Anatomy, University of Bern, Bern, Switzerland. 6Harvard College, Cambridge, Massachusetts, USA. 7Department of Pathology and Immunology and Department of Medical Specializations – Cardiology, University of Geneva, Geneva, Switzerland. 8Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 9Spanish National Cancer Research Centre, Madrid, Spain. 10Ludwig Center for Cancer Research, University Lausanne, Lausanne, Switzerland. 11Max Planck Institute for Molecular Biomedicine, Münster, Germany. 12Swiss Cancer Research Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

Biomechanical forces, such as fluid shear stress, govern multiple aspects of endothelial cell biology. In blood vessels, disturbed flow is associated with vascular diseases, such as atherosclerosis, and promotes endothelial cell proliferation and apoptosis. Here, we identified an important role for disturbed flow in lymphatic vessels, in which it cooperates with the transcription factor FOXC2 to ensure lifelong stability of the lymphatic vasculature. In cultured lymphatic endothelial cells, FOXC2 inactivation conferred abnormal shear stress sensing, promoting junction disassembly and entry into the cell cycle. Loss of FOXC2-dependent quiescence was mediated by the Hippo pathway transcriptional coactivator TAZ and, ultimately, led to cell death. In murine models, inducible deletion of Foxc2 within the lymphatic vasculature led to cell-cell junction defects, regression of valves, and focal vascular lumen collapse, which triggered generalized lymphatic vascular dysfunction and lethality. Together, our work describes a fundamental mechanism by which FOXC2 and oscillatory shear stress maintain lymphatic endothelial cell quiescence through intercellular junction and cytoskeleton stabilization and provides an essential link between biomechanical forces and endothelial cell identity that is necessary for postnatal vessel homeostasis. As FOXC2 is mutated in lymphedema-distichiasis syndrome, our data also underscore the role of impaired mechanotransduction in the pathology of this hereditary human disease.

Introduction

Active and complex signaling is involved both in the growth of new vessels and their stabilization and maintenance. Blood vessel stabilization encompasses proliferation arrest, restoration of the vascular barrier function, and acquisition of mural cell coverage. These properties need to be maintained for the lifetime of the organism to ensure optimal perfusion and tissue homeostasis (1). Laminar blood flow is an important vessel-stabilizing factor: it contributes to the termination of angiogenic signaling and vessel specialization through oxygenation of tissues and mechanoregulation of endothelial cells (2). In contrast, disturbed blood flow induces endothelial dysfunction, involving proinflammatory signaling, enhanced proliferation, and apoptosis, which ultimately lead to pathological responses like the formation of atherosclerotic lesions (2).

In addition, blood vessel stability and integrity require mature cell-cell junctions and mural cell coverage. Molecular players implicated in the regulation and maintenance of vascular stability include β-ANG1/TIE2, FGF, Notch, SIP, PDGF-β and TGF-β signaling, extracellular matrix, and proteases. Important progress has already been achieved in our understanding of the molecular regulation of blood vessel stability (3). However, little is known about the processes involved in stabilization of the lymphatic vasculature, despite its key role in normal homeostasis and in a variety of pathological conditions, such as tumor metastasis and chronic inflammation (4).

The lymphatic vasculature comprises two structurally and functionally distinct compartments: capillaries and collecting vessels. Interstitial fluid and immune cells enter via discontinuous intercellular junctions in lymphatic capillaries and are transported by collecting vessels to lymph nodes as a result of coordinated contractions of vascular smooth muscle cells, valve opening, and closure cycles and pressure gradients from surrounding tissues (5). Such functional separation is critically important for optimal lymphatic function (6, 7); yet how it is maintained throughout life remains to be defined.

Here, we interrogated the molecular mechanisms of postnatal collecting lymphatic vessel maintenance. We showed that collecting lymphatic vessel function requires continuous expression of the forkhead transcription factor FOXC2 in areas of disturbed flow, such as lymphatic valves. FOXC2 controls endothelial cytoskeleton organization and thus ensures cell-cell junction stability, endothelial integrity, and cell-cycle arrest under disturbed flow conditions.

Authorship note: Esther Bovay and Cansaran Saygili Demir contributed equally to this work.
Conflict of Interest: The authors have declared that no conflict of interest exists.
Submitted: December 11, 2014; Accepted: August 13, 2015.
The rapid onset of lymphatic vascular dysfunction makes it especially suitable for therapeutic preclinical studies. We further showed that FOXC2 secures cell dormancy by blocking proliferation mediated by the mechanosensitive Hippo pathway transcriptional coactivator TAZ. Our work establishes a general principle of postnatal lymphatic vascular organization in which FOXC2 plays a central role in maintaining collecting vessel quiescence and stability, notably in valve areas, by linking shear stress responses to cell junction stabilization and cell-cycle arrest. FOXC2 is mutated in lymphedema-distichiasis, a debilitating human disease, characterized by lymphedema of the lower limbs and valve defects (8). Our work now provides a robust mouse model, in which the rapid onset of lymphatic vascular dysfunction makes it especially suitable for therapeutic preclinical studies.

Results

**FOXC2 is highly expressed in areas of flow recirculation.** FOXC2 plays an important role in the initiation of embryonic collecting lymphatic vessel formation (7, 9). We found that FOXC2 continues to be highly expressed in the postnatal collecting lymphatic vessels (Figure 1A). In agreement with the previously demonstrated induction of FOXC2 expression by oscillatory shear stress (OSS) in vitro (10), FOXC2 levels were highest in lymphedema-distichiasis, a debilitating human disease, characterized by lymphedema of the lower limbs and valve defects (8). Our work now provides a robust mouse model, in which the rapid onset of lymphatic vascular dysfunction makes it especially suitable for therapeutic preclinical studies.

**FOXC2 regulates shear stress–induced quiescence and survival.** To analyze whether FOXC2 regulates responses to disturbed flow, we studied LECs cultured under static or oscillatory flow conditions, which mimic disturbed flow (11). We first analyzed the transcriptome of LECs subjected to OSS, in the presence or absence of FOXC2 (control or FOXC2KD cells, respectively), and compared them to cells cultured under static conditions (Figure 2A and Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI80454DS1). In control cells, OSS affected the expression of over 800 genes (FDR < 0.05, Figure 2B and see validation by qPCR in Supplemental Figure 1, B–D). Analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (12, 13) revealed important rewiring of LEC metabolism by OSS, as demonstrated by activation of steroid and terpenoid backbone biosynthesis, glutathione metabolism, and the pentose phosphate pathway (Supplemental Table 1). Surprisingly, cell cycle and mitosis pathways were the most significantly repressed KEGG pathways, as evidenced by a concerted decreased expression of genes associated with cell-cycle progression (Supplemental Table 1). This result was unexpected, as disturbed flow is a known inducer of proliferation in blood endothelial cells (BECs) (11).

**FOXC2 inactivation modified the expression of 35% of the shear stress–responsive genes, demonstrating that FOXC2 regulates a significant proportion of LEC shear stress transcriptional responses (Figure 2B).** FOXC2KD cells demonstrated an abnormal shear stress response, as observed by reduced expression of known shear stress-responsive genes, such as eNOS and CX37 (refs. 10, 14, and Supplemental Figure 1, B and C). Most strikingly, cell-cycle progression genes were no longer repressed by OSS in FOXC2KD cells, suggesting that cells fail to undergo growth arrest (Figure 2, C and D, and Supplemental Figure 1, E and F). In contrast, FOXC2 knockdown did not affect OSS-dependent suppression of the genes related to immune responses or OSS-dependent induction of the genes related to cholesterol biosynthesis (Figure 2, C and D), suggesting a specific role of FOXC2 in the OSS-induced downregulation of cell proliferation.

We next analyzed LEC proliferation in static and OSS conditions by staining for the proliferation marker Ki67 (Figure 3, A and B). Low but detectable proliferation of LECs in static conditions was significantly decreased by OSS (Figure 3B). Surprisingly, but in agreement with the transcriptome analyses (Figure 2, C and D), FOXC2KD cells displayed a 10-fold increase in the number of Ki67+ cells in OSS when compared with that of control cells. This finding was further confirmed by the analysis of DNA synthesis and the use of a second FOXC2 siRNA (Supplemental Figure 2, A–C).

In BECs, disturbed flow induces not only cell proliferation, but also cell death (11). To study whether FOXC2 regulates cell survival, we stained cells for the apoptosis marker activated caspase-3. However, we could not detect any apoptotic cells under OSS (data not shown), likely due to their rapid elimination by the flow. To overcome this limitation, we performed a time-lapse microscopy analysis. We found that OSS induced the death and quick detachment of some
control cells (Figure 3, C and D, and Supplemental Videos 1 and 2). Importantly, we observed increased proliferation of \( \text{FOXC2}^{\text{KD}} \) cells under OSS, which was also accompanied by increased cell death (Figure 3, C and D, and Supplemental Videos 3 and 4).

Endothelial cells actively migrate during sprouting (lymph) angiogenesis, whereas the motility of endothelial cells in quiescent vessels is reduced, which is important for overall vessel stability (3). To evaluate whether FOXC2 plays a role in LEC motility, we tracked the movement of control and \( \text{FOXC2}^{\text{KD}} \) cells in the presence and absence of OSS. LECs were highly motile under static conditions and became immobilized under OSS (Figure 3E and Supplemental Videos 5 and 6), suggesting stabilization of the endothelial monolayer. In contrast, although \( \text{FOXC2}^{\text{KD}} \) LECs were less motile in static conditions, they migrated more in OSS (Figure 3E, Supplemental Figure 2D, and Supplemental Videos 7 and 8).

Thus, we conclude that in LECs OSS triggers growth and motility arrest, which may protect vessel integrity by reducing the cell turnover (Figure 3F). Of interest, although further studies are warranted, our data suggest that LECs respond differently to disturbed flow in comparison to BECs (11). Most importantly, FOXC2 plays a key role in such LEC responses, suggesting that FOXC2 acts as a guardian of LEC quiescence and survival in disturbed flow conditions.
Exposure to OSS resulted in the transformation of such linear junctions into overlapping contact sites, often assembled into a complex reticular adherens network (Figure 4, A–C), which has been previously described in quiescent BECs (17). Taken together with the fact that OSS induces LEC quiescence and motility arrest, this observation suggests that OSS stabilizes cell-cell junctions. Induc-

**FOXC2 controls cell-cell junction and cytoskeleton organization in a cell-autonomous manner.** Given the known relevance of cell-cell junctions in contact inhibition of growth (15), we next analyzed whether FOXC2 regulates lymphatic endothelial intercellular junctions. As previously described (16), control LECs displayed mostly linear intercellular junctions in static conditions (Figure 4, A–C). Exposure to OSS resulted in the transformation of such linear junctions into overlapping contact sites, often assembled into a complex reticular adherens network (Figure 4, A–C), which has been previously described in quiescent BECs (17). Taken together with the fact that OSS induces LEC quiescence and motility arrest, this observation suggests that OSS stabilizes cell-cell junctions. Induc-
FOXC2 and OSS control adherens cell-cell junction integrity. (A) Staining of control and FOXC2+ cells for FOXC2 (green) and VE-cadherin (pink). The arrow indicates an overlapping junction induced by OSS; the arrowhead indicates a zigzag-like junction induced by FOXC2 depletion. Cell nuclei are outlined by white lines. (B) High-magnification images of VE-cadherin junctions (black) show the formation of reticular structures (red arrow) in control cells under OSS, while FOXC2 cells have mostly discontinuous and thin cell-cell contacts (red arrowhead). (C) Quantification of adherens cell-cell junction types in control and FOXC2+ cells. VE-cadherin junctions were classified as linear (exemplified by control/static image in B), overlapping (exemplified by control/oscillatory image in B), or discontinuous (exemplified by FOXC2/oscillatory image in B). The proportion of each junction type was determined for the entire cell periphery. (D) OSS increases VE-cadherin junctional area in control but not in FOXC2+ LECs. (E) Increased junction complexity in FOXC2+ cells, as indicated by increased fractal dimension of the VE-cadherin organization. (F) Increased number of VE-cadherin gaps in FOXC2+ LECs. (G) FOXC2-dependent cell-cell junction remodeling is cell autonomous. The isolated FOXC2+ cell has continuous junctions (arrows), while the neighboring FOXC2+ cells have zigzag junctions (arrowheads). Staining for FOXC2 (green) and VE-cadherin (pink). Cell nuclei are outlined with dashed white lines. Scale bars: 10 μm (A and G); 5 μm (B). n = 3; more than 50 cells scored per condition; 2-tailed unpaired Student’s t test; *P < 0.05 (control vs. OSS), *P < 0.05 (control vs. FOXC2+); (see also Supplemental Figure 3, A and B).

Figure 4. FOXC2 and OSS control adherens cell-cell junction integrity. (A) Staining of control and FOXC2+ cells for FOXC2 (green) and VE-cadherin (pink). The arrow indicates an overlapping junction induced by OSS; the arrowhead indicates a zigzag-like junction induced by FOXC2 depletion. Cell nuclei are outlined by white lines. (B) High-magnification images of VE-cadherin junctions (black) show the formation of reticular structures (red arrow) in control cells under OSS, while FOXC2+ cells have mostly discontinuous and thin cell-cell contacts (red arrowhead). (C) Quantification of adherens cell-cell junction types in control and FOXC2+ cells. VE-cadherin junctions were classified as linear (exemplified by control/static image in B), overlapping (exemplified by control/oscillatory image in B), or discontinuous (exemplified by FOXC2/oscillatory image in B). The proportion of each junction type was determined for the entire cell periphery. (D) OSS increases VE-cadherin junctional area in control but not in FOXC2+ LECs. (E) Increased junction complexity in FOXC2+ cells, as indicated by increased fractal dimension of the VE-cadherin organization. (F) Increased number of VE-cadherin gaps in FOXC2+ LECs. (G) FOXC2-dependent cell-cell junction remodeling is cell autonomous. The isolated FOXC2+ cell has continuous junctions (arrows), while the neighboring FOXC2+ cells have zigzag junctions (arrowheads). Staining for FOXC2 (green) and VE-cadherin (pink). Cell nuclei are outlined with dashed white lines. Scale bars: 10 μm (A and G); 5 μm (B). n = 3; more than 50 cells scored per condition; 2-tailed unpaired Student’s t test; *P < 0.05 (control vs. OSS), *P < 0.05 (control vs. FOXC2+); (see also Supplemental Figure 3, A and B).

intercellular tensional cytoskeletal forces and regulation of RhoA/ROCK/MLC signaling. We also analyzed the distribution of vinculin, which anchors actin fibers to focal adherens junctions between cells or focal adhesions to the cell matrix. Vinculin is a mechanosensing protein, which controls force-dependent junction remodeling by integrating the cytoskeleton tensional forces and protecting junc-
tions from disrupting under such forces (18). Vinculin levels were augmented in junctional areas between FOXC2KD cells when compared with control cells, suggesting higher intercellular traction forces and loss of junction integrity (Figure 5B).

In conclusion, LECs normally adapt to oscillatory flow by reinforcing cell-cell junctions. Such increased overlapping interaction surface, associated with cortical actin cytoskeleton at the cell-cell junction, is likely important for providing resistance to mechanical stress. Loss of FOXC2 prevents the formation of overlapping junctions and leads to profound remodeling of the cell cytoskeleton, increased actomyosin contractility, and formation of discontinuous cell-cell junctions, prone to disruption when subjected to mechanical forces (Figure 5C). Thus, we propose that FOXC2 is necessary for stabilization of cell-cell junctions and the ability of cells to withstand mechanical stress.

**FOXC2 buffers YAP1/TAZ signaling in LECs.** FOXC2-depleted LECs respond to OSS by cytoskeleton hypercontractility, intercellular junction disruption, aberrant proliferation, and, ultimately, increased cell death. We hypothesized that the observed cytoskeletal and junctional changes relieve the contact inhibition, thus initiating proliferation of FOXC2KD cells. Mechanotransduction regulates cell proliferation via cytoplasmic versus nuclear localization of YAP1/TAZ transcriptional coactivators, which can also be sequestered by junction molecules, such as catenins and angiомотins (19, 20). Contact inhibition of cell growth is triggered through inactivation of YAP1/TAZ, whereas low cell density or loss of cell-cell contacts induces nuclear translocation of YAP1/TAZ and subsequent activation of cell cycle (15, 21).

Analyses of genes regulated by OSS in the presence or absence of FOXC2 revealed that FOXC2KD cells expressed higher levels of YAP1/TAZ target genes CTGF, CYR61, and ANKRDI (22), and this effect was further potentiated under OSS (Figure 6A), suggesting that FOXC2 restricts the activation of YAP1/TAZ signaling by oscillatory flow. Staining of LECs demonstrated that OSS increased nuclear localization of YAP1/TAZ in both control and FOXC2KD cells (Figure 6, B and C). However, while YAP1/TAZ was detected in control cell-cell junctions, it was mostly nuclear and absent from junctions in FOXC2KD cells (Figure 6B and Supplemental Figure 4A). These results were in line with in vivo analyses, which demonstrated nuclear localization of TAZ and YAP1 in lymphatic valves (Figure 6D and data not shown). To study whether YAPI/TAZ play a functional role in FOXC2KD cells, we silenced YAPI and TAZ in FOXC2-depleted cells and analyzed cell proliferation in OSS by staining for Ki67. We found that YAPI/TAZ knockdown significantly reduced the hyperproliferation of FOXC2KD cells (Figure 6E and Supplemental Figure 4B). Surprisingly, knockdown of YAPI had no effect on the number of Ki67+ cells (Figure 6F), despite significant YAPI downregulation (Supplemental Figure 4C). In contrast, depletion of TAZ with 2 different siRNAs abrogated the aberrant proliferation of FOXC2KD cells, without affecting junction organization (Figure 6G and Supplemental Figure 4D–F). Interestingly, TAZ inactivation alone, in addition to reducing the expression of the TAZ target genes CTGF, CYR61, and ANKRDI (Supplemental Figure 4G), was sufficient to decrease the proliferation of LECs in static conditions (Supplemental Figure 4H).

Collectively, these data highlight the role of cell-cell junctions and cytoskeleton organization in the control of LEC quiescence.
in response to OSS. These results suggest that, while OSS is able to increase YAP1/TAZ nuclear translocation, FOXC2 efficiently blocks the pro-proliferative effect of TAZ and thus safeguards LEC quiescence and survival under disturbed flow conditions.

**FOXC2 is essential for postnatal lymphatic vascular function.** To assess the role of FOXC2 in the postnatal lymphatic vasculature in vivo, we generated a lymphatic endothelial-specific, tamoxifen-inducible loss-of-function mouse model (\(\text{Foxc2}^{\text{fl/fl}}\) \(\text{Prox1-Cre}^{\text{ERT2}}\) [\(\text{Foxc2}^{\text{lecKO}}\)]) (Supplemental Figure 5, A–D). Inactivation of \(\text{Foxc2}\) led to fully penetrant mortality, with the onset varying from a few days during early postnatal inactivation to up to 5 months in adult mice (Figure 7A and data not shown). Macroscopic analyses demonstrated development of chylous ascites and chylothorax in \(\text{Foxc2}^{\text{lecKO}}\) animals (Figure 7B). Further examination revealed dilated submucosal lymphatic vessels in the small intestine and chyle-filled lymphatic vessels in the cecum, which normally does not receive chyle because of efficient fat absorption in the duodenum and the jejunum (Figure 7C). We also observed Peyer’s patches filled with chyle (Figure 7C). Occasionally, chyle-filled lymphatic vessels were also observed in other internal organs, such as the heart (Supplemental Figure 5E). Mesenteric lymphatic collecting vessels were often surrounded by chyle effusion in \(\text{Foxc2}^{\text{lecKO}}\) animals (Figure 7C).
Figure 7. FOXC2 is essential for postnatal lymphatic vascular function. (A) Time course of chylous effusion (pink curve) and lethality (green curve) after Foxc2 inactivation. The dotted line indicates the time point used for most phenotypic analyses. Chylous effusion was defined as the presence of chylothorax or chylous ascites. n = 150 animals (5–20 Foxc2^{lox/lox} mice per time point). (B) Macroscopic appearance of chylothorax (top row) and chylous ascites (bottom row) in P8 Foxc2^{lox/lox} mice. The arrowheads indicate chyle. (C) Chyle accumulation in the intestinal submucosal lymphatic vessels, in the cecum, and in Peyer’s patches (asterisk) and chyle leakage from mesenteric lymphatic collecting vessels in P8 Foxc2^{lox/lox} mice. Black arrowheads indicate chyle accumulation. The white arrow indicates mesenteric vessels. White arrowheads indicate valves. Red arrows indicate chyle leakage. (D) Lymph reflux from the thoracic duct and from dermal collecting lymphatic vessels in P8 Foxc2^{lox/lox} mice. Collecting lymphatic vessels were visualized by FITC-dextran injection into the mesenteric lymph node (top row) or the forelimb foot pad (bottom row). Asterisks indicate thoracic ducts. Arrowheads indicate backflow into lymphatic branches. FL, forelimb; LN, axillary lymph node. (E) Impaired lymph transport in Foxc2^{lox/lox} Prox1-mOrange2{sup} pups at P8. FITC-dextran was injected into the inguinal lymph node (asterisks) and visualized in the dermal efferent collecting vessel. Foxc2^{lox/lox} animals often showed arrest of the lymph drainage at the site of a misshapen valve with lumen narrowing. Arrowheads indicate valves (see also Supplemental Figure 5). Scale bars: 2 mm (B); 250 μm (C); 1 mm (D); 500 μm (E).

These data suggested a highly abnormal lymph transport in Foxc2^{lox/lox} mice. To analyze the lymphatic drainage, we injected fluorescent FITC-dextran into the mesenteric lymph nodes of control or Foxc2^{lox/lox} mice. As expected, we observed filling of the thoracic ducts in control mice (Figure 7D). In contrast, Foxc2^{lox/lox} mice had dye outflow in multiple afferent collecting lymphatic vessel branches, indicating lymph backflow. This observation was confirmed by dye injection into the foot pads or the inguinal lymph nodes (Figure 7, D and E). Of interest, Foxc2^{lox/lox} collecting lymphatic vessels were abnormally patterned, with alternating areas of vessel ectasia and constrictions (Figure 7E).

Taken together, these data demonstrate that the continuous expression of FOXC2 is required for postnatal lymphatic vascular function.
FOXC2 maintains the postnatal collecting lymphatic vessel phenotype. We next crossed the Foxc2<sup>lecko</sup> line with the Prox1-mOrange2 reporter strain, which allows better detection of LECs through the expression of a fluorescent transgene (refs. 10, 23, and Supplemental Figure 5B). In particular, lymphatic valves can be clearly identified, due to high levels of Prox1 expression in the leaflets.

Quantification demonstrated that numerous valves were already present in mesenteric lymphatic vessels at birth and that their number continued to increase during postnatal development, in line with the continuous animal growth at this stage (Figure 8A). Control mesenteries at P8 showed well-developed collecting lymphatic vessels, characterized by even lymphangion diameter, and up to 800 valves positioned at regular intervals along the mesenteric vessels (Figure 8, A and B). Inactivation of Foxc2 induced degeneration of the lymphatic valves, leading to a significant decrease both in the total number of valves and in the proportion of fully formed valves containing 2 intraluminal leaflets (Figure 8B-D). The number of valves in Foxc2<sup>lecko</sup> mice was lower than that at the beginning of tamoxifen administration, demonstrating that Foxc2 inactivation affects both growing and established lymphatic valves (Figure 8D). A similar phenotype was observed when using the Flt4-Cre<sup>ERT2</sup> deleter strain to inactivate Foxc2 in the lymphatic endothelium (Supplemental Figure 6, A-C).

The spectrum of lymphatic valve defects in Foxc2<sup>lecko</sup> mice ranged from shortened leaflets to an almost complete absence of PROX1<sup>hi</sup> valve cells (Figure 8C), with vessel constriction often being the only sign of the former valve location. As Foxc2 deletion in lymphatic valves was nearly complete (Supplemental Figure 5D), the variability in the severity of valve defects may be related to local conditions, such as changes in flow. Fluorescent microlymphangiography demonstrated greatly reduced or absent flow through stenotic valve areas, suggesting vessel lumen obstruction (Figure 7E). Surprisingly, in a significant proportion of Foxc2<sup>lecko</sup> lymphatic vessels, as shown in C, n = 4–6; 4 vessels were scored per mesentery; 2-tailed unpaired Student’s t test; *P < 0.05. Scale bars: 1 mm (B); 50 μm (C).
Foxc2−/− adult mice displayed reduced resistance to increasing backflow pressures and leakiness (Figure 9B and Supplemental Figure 7, E and F) due to leaflet regression (Figure 9A).

Intraluminal valves, smooth muscle cell coverage, and lack of expression of lymphatic capillary markers, such as LYVE-1, are distinguishing features of collecting lymphatic vessels (6, 7). Lymphatic valve endothelial cells produce high levels of specialized extracellular matrix proteins, such as laminin α5 (24). Valve degeneration in Foxc2−/− animals was associated with disruption and detachment of the laminin α5 valve matrix (Figure 10A). Overall, smooth muscle cell recruitment to lymphangions was not significantly affected in Foxc2−/− mice; in contrast, areas of degenerating valves were frequently covered with mural cells, while they were sparse in the valve areas of control mice (Figure 10B). Consistent with previous reports, LYVE-1 was virtually absent from the collecting vessels of wild-type mice (refs. 6, 9, 25, and Figure 10C). However, we observed widespread ectopic reexpression of LYVE-1 in the mesenteric lymphatic vessels of Foxc2−/− mice (Figure 10, C and D).

Taken together, these data demonstrate that FOXC2 is necessary for postnatal development and maintenance of key characteristics of the collecting vessels, such as intraluminal valves, patterning of vascular smooth muscle cells, and appropriate vascular luminal size (Figure 10E).

FOX2 controls cell shape and cell-cell junctions in vivo. Loss of valves in Foxc2−/− mice demonstrates a critical role for FOX2 not only in postnatal lymphatic valve development, but also in maintenance. It also raises the question of whether regression of valve leaflets is sufficient to explain the lethal phenotype of Foxc2−/− mice. Gap junction protein connexin37 (CX37) is regulated by FOXC2 during embryonic development, and Cx37−/− mice have severe impairment of lymphatic valve formation and lymph flowback (10, 26). However, Cx37−/− mice, which lack lymphatic valves to the same extent as Foxc2−/− animals, did not develop chylous ascites or chylothorax and survived normally into adulthood (Supplemental Figure 8, A and B, and data not shown). Thus, while valve degeneration explains lymph backflow (Figure 7D), it is not sufficient to account for chyle leakage and for the generalized collecting lymphatic vessel dysfunction observed in Foxc2−/− mice.

Endothelial cells in lymphatic capillaries have discontinuous cell-cell junctions, which are important for the unimpeded uptake of interstitial fluid. In contrast, endothelial cells in collecting vessels are connected by continuous “zipper-like” junctions, which minimize the loss of lymph during its transport (27). Junction disruption in FOXC2−/− cells in vitro and increased lymph leakage in Foxc2−/− mice suggest a loss of vascular barrier integrity (Figure 4 and Figure 7C). Therefore, we investigated the state of endothelial junctions by staining collecting lymphatic vessels for VE-cadherin. Endothelial cells in collecting vessels of wild-type mice were elongated in the direction of lymph flow and displayed continuous linear cell-cell junctions with high levels of VE-cadherin (Figure 11, A and B). However, only 3 days after Foxc2 inactivation, cells already had a more rounded shape (Figure 11, A and B). Most importantly, continuous linear cell-cell junctions were replaced by distinct zigzag-like junctions (Figure 11, B and C). At later stages, reduced and punctuated VE-cadherin staining was observed, demonstrating a disruption of intercellular junctions (Supplemental Figure 9A). This was in agreement with our in vitro observation of intercellular gaps formed in FOXC2−/− cells under oscillatory and, to a lesser extent, laminar shear stress (Figure 4, B and F, and Supplemental Figure 9B). In addition, endothelial junction protein claudin5, which is highly expressed in wild-type collecting vessels, was also reduced in Foxc2−/− degenerating valve areas (Supplemental Figure 9C).

We further examined the morphology of endothelial cell-cell junctions in the thoracic duct using transmission electron microscopy. In wild-type mice, endothelial cells formed a thin and continuous monolayer surrounded by a thick and dense basement membrane (Figure 11D). However, in Foxc2−/− animals, the endothelium appeared disrupted in several sites and associated with a loose and disorganized extracellular matrix, indicative of increased endothelial permeability (Figure 11D). Surprisingly, disruption of the endothelium was characterized by the formation of large vacuole-like structures, which formed thin sheet-like fragments shedding into the lumen (Figure 11D). Further examination of cell-cell contacts revealed that wild-type endothelial cells had well-organized interdigitating contacts tightly bound to the matrix (Figure 11, E–G). However, the majority of such contacts in Foxc2−/− cells were unfolded, resulting in the formation of large vacuoles and endothelial cell detachment from the matrix below (Figure 11, D–G), indicating severe loss of intercellular junction integrity.

Thus, we propose that loss of junction integrity in the absence of FOXC2 is responsible for lymph leakage and development of chyloous effusion (Figure 10E). In addition, such vessels may be
FOXC2 controls cell quiescence and survival in vivo. We next sought to investigate the cellular mechanisms implicated in valve regression and lumen collapse at the former valve site. The number of PROX1hi valve cells was reduced in Foxc2lecKO vessels already 2.5 days after tamoxifen administration (Supplemental Figure 10A and Supplemental Video 9). We examined LEC apoptosis in control and Foxc2lecKO mice by staining for activated caspase-3 and PROX1. While apoptosis was barely detectable in wild-type samples, a significant number of apoptotic cells were observed in the valves of Foxc2lecKO vessels (Figure 12, A and B). A careful examination revealed that Foxc2lecKO apoptotic cells were often arranged in doublets with symmetrically organized PROX1hi apoptotic bodies (Figure 12, C and D), indicating that apoptosis might occur in dividing cells. To address this question, we stained wild-type and Foxc2lecKO mesenteries for PROX1 and the cell proliferation marker Ki67 to identify proliferating LECs that undergo cell death. Surprisingly, but in line with our in vitro results, a markedly higher proportion of PROX1+/Ki67+ cells was found in Foxc2lecKO collecting vessels compared with that in control collecting vessels (Figure 12E), demonstrating increased cell proliferation. Interestingly, 78.7% ± 13.7% of the Foxc2lecKO valves (n = 3 animals) showed at least one cell death event, which was characterized by PROX1hi apoptotic bodies (Figure 12F and ref. 28). Half of the Foxc2lecKO dying cells (50.6% ± 27.9%, n = 3 animals; Figure 12G) were double positive for PROX1 and Ki67, further reinforcing the link between cell proliferation and death in Foxc2lecKO vessels. In contrast, we were unable to detect double-positive PROX1/Ki67 dying cells in the wild-type samples. We further validated the increased LEC proliferation in Foxc2lecKO vessels, using the EdU incorporation assay to detect DNA synthesis (Figure 13, A and B). A significantly higher proportion of proliferating LECs...
10E). Cx37 levels were decreased in Foxc2<sup>−/−</sup> cells, in line with previously published results (Figure 13E, Supplemental Figure 10E, and refs. 10, 26). Most importantly, FOXC2-deficient valve LECs expressed higher levels of the YAP1/TAZ targets Ctgf, Cyr61, and Ankrd1, further supporting the notion that FOXC2 restricts TAZ activity in vivo (Figure 13F and Supplemental Figure 10E).

Collectively, these experiments suggest that FOXC2 is important for the maintenance of collecting vessel endothelial cell quiescence and survival. In the absence of FOXC2, LECs undergo TAZ-dependent inappropriate proliferation, which is also accompanied by increased apoptosis, resulting in valve cell loss and vessel lumen narrowing.

Inactivation of FOXC2 only in the valve areas recapitulates the postnatal lethality phenotype. Our in vitro data indicate that a combination of FOXC2 loss of function and increased mechanical strain, such as OSS, is necessary to disrupt cell-cell junctions and to

was found in Foxc2<sup>−/−</sup> collecting vessels compared with that in control collecting vessels (Figure 13C), while lymphatic capillaries of both control and Foxc2<sup>−/−</sup> mice displayed comparable proliferation rates (Supplemental Figure 10B).

Our in vitro experiments suggested that enhanced proliferation in the absence of FOXC2 is mediated by the increased activity of the Hippo pathway effector TAZ (Figure 6). Moreover, we observed TAZ nuclear localization in the lymphatic collecting vessels, particularly in valves (Figure 6D) and in Ki67<sup>+</sup> LECs in Foxc2<sup>−/−</sup> mice (Supplemental Figure 10C). To study TAZ activity in vivo, we isolated lymphangion and lymphatic valve endothelial cells from the mesenteric vessels of wild-type or Foxc2<sup>−/−</sup> Prox1-mOrange2 animals using FACS (Supplemental Figure 10D). As expected, valve cells expressed higher levels of the mOrange2 transgene and valve markers Prox1, integrin α9, and Cx37 in comparison to lymphangion cells (Figure 13, D and E, and Supplemental Figure 10E).
initiate abnormal cell proliferation and death, which would impair lymphatic vascular function in vivo. Therefore, inactivation of Foxc2 only in areas of disturbed flow, such as valves, should recapitulate the lethal phenotype observed in mice with inactivation of Foxc2 in all LECs. To test this hypothesis, we generated Foxc2<sup>fl/fl</sup> Prox1-Cre<sup>ERT2</sup> Rosa26-YFP and Prox1-Cre<sup>ERT2</sup> Rosa26-YFP mice, in which administration of tamoxifen genetically marks recombined cells with YFP. We next titrated the dosage of tamoxifen to 3 μg/g to achieve a mosaic deletion of Foxc2 in P4 mice. At this concentration, recombination was observed in 5% to 10% of cells, preferentially in the valve areas, likely due to higher Prox1 promoter activity (Figure 14A). We quantified the number of YFP<sup>+</sup> cells in the lymphatic vessels of control and Foxc2<sup>lecKO</sup> animals 2 days after tamoxifen injection, which was prior to the appearance of valve structure defects. There was a significant decrease in the number of YFP<sup>+</sup> cells in Foxc2<sup>lecKO</sup> mice compared with that in wild-type valves, while YFP expression was comparable in other Prox1-expressing tissues, such as eye lenses, in the control and Foxc2<sup>lecKO</sup> mice (Figure 14 and data not shown). These data are in line with the observed increased apoptosis (Figure 12, A and B), and they confirm that Foxc2-deficient cells were rapidly eliminated from valve regions. Most importantly, such localized inactivation of FOXC2 resulted in the development of chylothorax and fully penetrant animal lethality (0 of 7 Foxc2<sup>lecKO</sup> mice vs. 6 of 6 control mice were alive 2 weeks after tamoxifen injection), thus recapitulating the defect of lymphatic vessels with complete inactivation of Foxc2. As a marked proportion of the PROX1<sup>hi</sup> leaflet cells was in direct contact with the PROX1<sup>hi</sup> lymphangion cells (Supplemental Figure 11), junctional defects and the abnormal proliferation/apoptosis rate of such FOXC2-deficient PROX1<sup>hi</sup> cells likely lead not only to valve leaflet regression, but also to vessel wall disruption, lymph leakage, and subsequent mouse death. We therefore propose that lymphatic valve areas represent critically vulnerable regions in collecting lymphatic vessels, which require especially high levels of FOXC2 to ensure vessel integrity and normal function of the entire lymphatic vessel network.

Discussion

Quiescence, barrier integrity, and functional specialization are key properties of the postnatal vasculature. At present, little is known about the regulation of these traits in lymphatic vessels, despite increasing understanding of their importance in both normal physiology and many diseases, such as cancer, inflammation, obesity, hypertension, and atherosclerosis (4, 5). Our ability to therapeutically modulate lymphatic vascular function — and thus potentially treat some of the major diseases — needs better understanding of the molecular processes important for lymphatic vascular stabilization, specialization, and maintenance. Here, we report that function of postnatal collecting lymphatic vessels critically depends on the transcription factor FOXC2.

By using an inducible loss-of-function genetic mouse model, we show that, in the absence of FOXC2, there is a rapid loss of collecting lymphatic vessel specialization and function. Such...
Inactivation of FOXC2 leads to loss of mature intercellular junctions and to actin cytoskeleton reorganization, which, we believe, is the initial defect that propagates lymphatic vascular dysfunction by several mechanisms. First, it impairs the collecting vessel barrier function and promotes lymph leakage, directly accounting for the development of chylous effusion (Figure 7, B and C, and Figure 15). Second, it modifies the responses of LECs to fluid shear stress: while disturbed flow promotes the quiescence of FOXC2+ LECs, in the absence of FOXC2, cells respond by activating TAZ signaling, which is further translated into enhanced cell proliferation followed by cell death (Figure 15). YAP1/TAZ are Hippo signaling effectors that play a key role in regulating organ size and tissue growth as well as in cancer (29, 30). However, the role of YAP1/TAZ in endothelial cells is not well understood. While YAP1 seems to have a dominant pro-proliferative function in most cell types, including HUVECs (31, 32), our analyses surprisingly revealed that, in LECs, TAZ, but not YAP1, is a critical regulator of proliferation in OSS and likely other conditions. Another intriguing observation is the fact that OSS induces not only FOXC2 KD cell proliferation, but also cell death. Progression through the cell cycle requires highly coordinated changes in actin cytoskeleton changes are characterized by degeneration of the lymphatic valves, decreased vascular barrier properties, ectopic endothelial proliferation and apoptosis, and loss of a patent vascular lumen at the sites of former valves (Figure 15). FOXC2 is highly expressed in the lymphatic valve sinuses, which are constantly solicited by complex fluid flow patterns and mechanical stretch, due to valve opening and closure (Figure 15). In addition, the valve site lacks smooth muscle cells, which normally provide prosurvival and stabilizing signals to the vascular endothelium (e.g., Figure 10B). Thus, we propose that continuous high FOXC2 expression is critical for the stability and function of these regions and, ultimately, normal function of the entire lymphatic vascular network.

We have shown previously that FOXC2 expression is induced by OSS (10). Here, we propose a model for the self-organization and maintenance of lymphatic valve regions in which FOXC2 plays a central role (Figure 15). In such a model, recirculating lymph flow, generated because of the geometry of the valves, induces high expression of FOXC2. FOXC2, in turn, maintains lymphatic valve leaflet and sinus integrity by stabilizing cell-cell junction and promoting quiescence and survival of cells subjected to disturbed flow (Figure 15). Inactivation of FOXC2 leads to loss of mature intercellular junctions and to actin cytoskeleton reorganization, which, we believe, is the initial defect that propagates lymphatic vascular dysfunction by several mechanisms. First, it impairs the collecting vessel barrier function and promotes lymph leakage, directly accounting for the development of chylous effusion (Figure 7, B and C, and Figure 15). Second, it modifies the responses of LECs to fluid shear stress: while disturbed flow promotes the quiescence of FOXC2+ LECs, in the absence of FOXC2, cells respond by activating TAZ signaling, which is further translated into enhanced cell proliferation followed by cell death (Figure 15). YAP1/TAZ are Hippo signaling effectors that play a key role in regulating organ size and tissue growth as well as in cancer (29, 30). However, the role of YAP1/TAZ in endothelial cells is not well understood. While YAP1 seems to have a dominant pro-proliferative function in most cell types, including HUVECs (31, 32), our analyses surprisingly revealed that, in LECs, OSS, TAZ, but not YAP1, is a critical regulator of proliferation in OSS and likely other conditions. Another intriguing observation is the fact that OSS induces not only FOXC2 KD cell proliferation, but also cell death. Progression through the cell cycle requires highly coordinated changes in actin cytoskel-
etion; therefore, it is possible that the abnormal state of the cytoskeleton in FOXC2<sup>−/−</sup> cells, which is especially striking in OSS (Figure 5), interferes with certain steps of cell division and leads to cell death.

In atherosclerosis, disturbed flow increases cell proliferation and apoptosis of blood arterial endothelial cells, leading to the formation of distinct areas with increased expression of proinflammatory genes and vascular permeability, which are thought to initiate the development of atherosclerotic plaques (33). While a side-by-side comparison of responses of different types of BECs and LECs to a range of shear stress values still needs to be carried out, it is of interest that the responses of FOXC2-deficient LECs, such as increased proliferation and cell death, are reminiscent of the BEC behavior in atheropone regions (2). Lymphatic valves are characterized by disturbed flow, and the mouse mesenteric vessel network contains up to 800 valves. Thus, unlike in blood vessels, areas of low OSS are very common in collecting lymphatic vessels. We therefore postulate that lymphatic vessels evolved a protective mechanism to keep such regions quiescent and functional through the mechanoinduction of FOXC2. In the absence of FOXC2, LECs might revert to the blood endothelial-specific dysfunctional phenotype and therefore be unable to withstand the valve mechanical stress.

FOXC2 is mutated in the human disease of lymphatic vessels, lymphedema-distichiasis, characterized by swelling of the lower limbs and valve defects (8). Since FOXC2 controls a significant part of the mechanoresponses of LECs, it is tempting to suggest that abnormal mechanotransduction is the primary cause of the defects observed in patients with lymphedema-distichiasis. Although 25% of Foxc2<sup>−/−</sup> mice are reported to develop lymphatic vascular defects (34), such incomplete penetrance complicates testing of potential treatment approaches for lymphedema-distichiasis. The rapid and fully penetrant onset of lymphatic vascular dysfunction in our model makes it especially suitable for therapeutic preclinical studies, such as screening of pharmacological agents.

In summary, our work reveals a key role of FOXC2 in the stabilization of collecting lymphatic vessels and maintenance of their function. It establishes a general principle of postnatal lymphatic vascular organization, in which the FOXC2 transcriptional network orchestrates collecting lymphatic vessel phenotype, quiescence, and integrity, through the coordination of cell-cell junction maturation and shear stress responses in the regions of disturbed flow, such as valves. It also uncovers a novel crosstalk between FOXC2 and TAZ in the regulation of LEC quiescence and proliferation. Finally, our work also reveals unexpected differences in the responses to the same mechanical stimuli by blood and LEC lineages. In addition, we suggest that further understanding of how lymphatic vessels avoid deleterious effects of disturbed fluid flow may provide useful information for the prevention or treatment of atherosclerosis.

**Methods**

**Animal models.** Generation of Foxc2<sup>fl/fl</sup> mice is described in Supplemental Figure 5A. Prox1-Cre<sup>ext</sup>, Flt4-Cre<sup>ext</sup>, Prox1-mOrange2, Rosa26-YFP, and Cx37<sup>−/−</sup> mice were described previously (Supplemental Figure 5B and refs. 23, 35–38). All mice were bred to at least the sixth generation on C57BL6/J background. Pups were injected with 125 μg tamoxifen in 50 μl sunflower oil i.p. or subcutaneously (Supplemental Figure 5C). For mosaic deletion, we used 3 μg/g tamoxifen. Adult mice were treated for 2 to 4 weeks, with 2 injections i.p. per week with 50 μg/g tamoxifen. 5 μg/g EdU (Life Technologies) was injected i.p. 3 hours prior to sacrifice.

**Microlymphangiography.** Anesthetized Prox1-mOrange2<sup>+</sup> mice were injected with 2 μl of 10 mg/ml 4-kDa FITC-dextran (Sigma-Aldrich) into forelimb foot pads or lymph nodes. Lymphatic drainage was observed under a Leica M205FA stereomicroscope, using Leica camera DFC300FXR2 and LAS AF6000 software.

**Mouse tissue collection, staining procedures, and image acquisition.** See the Supplemental Methods for detailed information. Supplemental Table 2 lists primary and secondary antibodies and dyes used in the study. All whole-mount staining images are shown with the same orientation, i.e., with the direction of flow from the bottom.

**Adult valve back-leak test.** Mesenteric lymphatic collecting vessel segments containing one valve were dissected from 8-week-old mice and analyzed as previously described (39, 40). A diagram of the preparation is shown in Supplemental Figure 7C. Briefly, output pressure (downstream) was elevated while monitoring pressure and diameter on the input (upstream) side of the valve (Supplemental Figure 7D). Two tests were performed at low (0.5–10 cm H<sub>2</sub>O at a rate of 4 cm H<sub>2</sub>O/min) or high (10–60 cm H<sub>2</sub>O with each step lasting for 30 seconds) pressure levels.

**Transmission electron microscopy.** Transmission electron microscopy was performed as previously described (41). Briefly, tissues were immersion fixed in 2.5% glutaraldehyde in PBS, post-fixed in osmium tetroxide, dehydrated in ethanol series, and embedded in epoxy resin. Ultrathin 90-nm sections were mounted on copper grids coated with Formvar (polyvinyl formal; Fluka), stained with lead citrate and uranyl acetate, and analyzed using a Philips EM 400 electron microscope.
Cell transfection and immunostaining. Human intestinal LECs were cultured as described previously (42). See the Supplemental Methods for detailed information. Supplemental Table 2 lists primary and secondary antibodies and dyes used in the study. siRNAs are listed in Supplemental Table 3. Two different siRNAs or a pool of four were used independently to knockdown the gene of interest. Knockdown efficiency was confirmed for each siRNA by RT-qPCR, Western blot analysis, and/or immunostaining (Figure 3A and Supplemental Figure 1A for FOXC2; Supplemental Figure 2B for a second FOXC2 siRNA; Supplemental Figure 4C for YAP1; and Supplemental Figure 4D for TAZ).

In vitro flow experiments. LECs were seeded at confluence on fibronectin-coated slides (μSlide 1μ Luer; ibidi), cultured for 24 hours, and subjected to oscillatory (4 dynes/cm²; 0.25 Hz, flow changes direction every 4 seconds) or laminar flow (4 dynes/cm²) in a parallel plate flow chamber system (ibidi Pump System; ibidi) or kept under static conditions in 2 independent groups by manual curation. The differences were considered statistically significant at P < 0.05. Data are shown as mean ± SD.

Gene expression and bioinformatics analyses. RNA was isolated from FOXC2 or control siRNA-transfected LECs subjected to 24 hours of OSS (1 dyn/cm²; 0.25 Hz) or kept under static conditions in 2 independent experiments using 2 different FOXC2 siRNAs. RNA was amplified and hybridized on Affymetrix Human Gene 1.0 ST Arrays, and arrays were scanned and analyzed as described previously (43). The data were corrected for batch effect with the COMBAT method and normalized using Robust Multichip Average (method Bioconductor package affy, R version 3.0.1). Data were submitted to Gene Omnibus (NCBI) under the accession number GSM1466659.

Pathway analyses were performed using R packages String.db and GOstat. The igraph package was used for network layout obtained in expression (NCBI) under the accession number GSM1466659. ReviGO was used to summarize GO enrichment lists into groups, and redundant groups were merged into biologically relevant groups by manual curation.

Flow cytometry. P14 mouse mesenteries were digested using Collagenase A (1 mg/ml, Roche)/DNase I (100 μg/ml, Roche) solution with 0.1% BSA. Cell suspension was filtered through a 40-μm cell strainer, washed with 5% FBS in phenol red-free DMEM (Gibco), and sorted on a BD FACSARia III (BD Biosciences) or MoFlo Astrios SQ (Beckman Coulter Life Sciences) cell sorter with BD FACS Diva software (BD Biosciences). Following exclusion of dead cells and multiplets, single mOrange2^- cells were gated using mOrange-PE and PE-TexasRed channels; cells from nontransgenic littermates were used to define the orange gate (Supplemental Figure 10D).

RNA isolation, qPCR, and Western blot analyses. For a full description, see the Supplemental Methods. A list of sequences of PCR primers is provided in Supplemental Table 4.

Quantification. For a full description, see the Supplemental Methods.

Statistics. We used a 2-tailed unpaired Student’s t test to determine statistical significance by calculating the probability of difference between two means. For valve back-leak test analyses, a custom LabVIEW program (National Instruments) was used to bin the data in 0.1- or 5-cm H2O increments for low- and high-pressure ramps, respectively. The binned data were imported into JMP 8 (SAS Institute) and analyzed using 1-way ANOVAs with Tukey-Kramer posthoc tests. The differences were considered statistically significant at P < 0.05. Data are shown as mean ± SD.

Study approval. Experiments were approved by the Animal Ethics Committee of Vaud, Switzerland, or by the University of Missouri Animal Care and Use Committee.
We thank L. Sorokin for laminin α5 antibodies; O. Dormond and J.M. Calmes for help with LEC isolation; C. Beuverd for mouse genotyping, colony maintenance, and help with immunohistochemistry; and S. Piccolo, D. Kerjaschki, G. Halder, and J. Bernard-Latmani for useful discussions. Animal, Cellular Imaging, Flow Cytometry, Genomic Technologies, and Mouse Pathology Facilities of the University of Lausanne are gratefully acknowledged. This work was supported by the Gebert Rhef Foundation, the Swiss National Science Foundation (PP0033-114898 to T.V. Petrova; CRSII3-141811 to T.V. Petrova, M. Delorenzi, and B.R. Kwak; 31003A_135740 to V. Djonov), La Fondation tatiana.petrova@unil.ch.

Address correspondence to: Tatiana V. Petrova, Department of Fundamental Oncology, CHUV-UNIL, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41.21.314.2968; E-mail: tatiana.petrova@unil.ch.